Clinical and Laboratory Evaluation of Response to Biological Agents in Rheumatoid Arthritis and Ankylosing Spondylitis

Authors : Hüsnü DEMİRCİ, Eylem KUDAY KAYKISIZ

Pages : 54-59

Doi:10.17678/beuscitech.459665

View : 35 | Download : 8

Publication Date : 2018-12-21

Article Type : Research Paper

Abstract :Our aim was to evaluate the anti-tumor necrosis factor insert ignore into journalissuearticles values(TNF); response to treatment, which has been in place in the treatment of Rheumatoid Arthritisinsert ignore into journalissuearticles values(RA); and Ankylosing Spondylitisinsert ignore into journalissuearticles values(AS); patients in recent years and has achieved successful results. In this regard, the follow-up of the disease is more predictable after the initiation of anti-TNF therapy; it is aimed to interpret the parameters used in follow-up more correctly. This cross-sectional, retrospective study was performed in auniversity hospital between 2010-2016. Files of 24 patients with AS and 53 patients with RAwere retrospectively screened. Their clinical situations and laboratory levels were compared before and after the biological agent treatment. Treatment response with RA was evaluated by Disease Activity Score-28 insert ignore into journalissuearticles values(DAS28); scale and AS patients’ treatment response was evaluated by Bath Ankylosing Spondylitis Disease Activity Index insert ignore into journalissuearticles values(BASDAI); scale.. A total of 77 patients were included in the study. Of the participants, 53 were diagnosed   as   RA   and   24   were   diagnosed   as   AS.   After   our   study   we   have   determined statistically   reasonable   decrease   in   C-Reactive   protein   insert ignore into journalissuearticles values(CRP);,   white   blood   cell   insert ignore into journalissuearticles values(wbc);, Platelete, erythrocyte sedimentation rate insert ignore into journalissuearticles values(ESR); levels but an increase in blood urea nitrogene insert ignore into journalissuearticles values(BUN);, haemoglobine insert ignore into journalissuearticles values(Hb);, Albumin levels. The mean baseline score of BASDAI assessed before the treatment in 24 patients with AS was 6.08 and after the treatment was 3.42; DAS-28 assessed before the treatment was 5,77 and after the treatment was 3,58 and these differences was statistically significant. Patients treated with biological agents showed a significant improvement in clinical assessment evaluated by BASDAI in patients with AS and DAS28 in patients with RA. Significant decrease in CRP, ESH, wbc levels, improvement in chronic disease anemia, increase in albumin level as a negative acute phase reactant and decrease in thrombocyte levels were determined because of acute phase response and regression of inflammation.
Keywords : BASDAI, DAS28, Ankylosing spondylitis, Rheumatoid arthritis